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Biotechnology in the Conquest of 
Infectious Diseases 
ASHLEY T. HAASE 
Ashley T Haase is Professor and Head of the Department of Microbiology at the University of Minnesota. 
I would like to discuss the enormous potential of biotech-
nology and molecular biology to benefit human medicine in 
the future, focusing on the applications of this technology to 
prevent and/ or treat infectious disease. 
I will first elaborate on the application of molecular biology 
to prevent viral disease. To provide a common basis for 
understanding, some basic concepts of virology are needed. 
Viruses are composed of a protein coat or capsid structure that 
surrounds a piece of deoxyribonucleic acid or DNA. The 
nucleic acid encodes all the information necessary to produce 
progeny virus in an infected cell. As obligate parasites, viruses 
enter a cell, reproduce their genetic material, subvert the cell 
to protein subcomponents that comprise the capsid, direct 
assembly of the newly synthesized DNA and proteins into 
progeny viral particles, and exit from the host cell. Viruses 
perform all of these functions not infrequently at the expense 
of the host cell and often show an amazing lack of gratitude for 
the efforts made on the part of the host cell. In the end, viruses 
may destroy the host cell, maim it in some fashion, or trans-
form it (resulting in the formation of a cancerous cell). Such 
effects at the cellular level cumulatively have an adverse effect 
on the health and well-being of the host animal. 
Vaccines have long been used to prevent these unfortunate 
consequences of viral infections. Not long ago, entire hospi-
tals were devoted to the care of patients with poliomyelitis, 
housed in row after row of iron lung machines. With the 
advent of the polio vaccine, these hospitals have thankfully 
ceased to exist. Vaccination involves using a preparation of 
virus that has been rendered inactive or noninfectious but is 
still capable of stimulating a protective immune response. 
Although traditional methods for producing viral vaccines 
have proven successful in ridding mankind of such scourges 
as polio and smallpox, developing vaccines for some other 
viruses has proven difficult. The techniques for manipulating 
DNA and proteins that are embodied in biotechnology permit 
the development of more effective vaccines. One such exam-
ple is the production of subunit vaccines, which are com-
posed of only the immunogenic protein components of the 
virus and are, therefore, noninfectious to the host. 
One of the first and most notable subunit vaccines devel-
oped via biotechnology is against hepatitis B. Hepatitis B virus 
is an enormous contributor to human morbidity, even some 
mortality, on a worldwide scale. As you may know, hepatitis B 
virus infects the liver, which results in dysfunction that is 
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readily seen as jaundiced skin. But the virus is also associated 
with hepatic cancer. Thus, prevention of this disease will have 
an enormous impact on two different serious diseases. Some 
time ago, a native or natural subunit vaccine was developed by 
purifying noninfectious viral particles from the blood of 
infected patients. Unfortunately, these particles were difficult 
and expensive to purify in quantity. They were also not partic-
ularly efficacious. More recently, virologists and molecular 
biologists have used recombinant DNA technology to cheaply 
produce in yeast cells a safe and effective hepatitis B vaccine. 
Restriction enzymes and nucleases were used to insert, or 
clone, pieces of the hepatitis B DNA( viral genes) that code for 
certain coat proteins into plasmids or other types of DNA 
vector systems that then transfer the viral DNA into yeast. The 
yeast are then manipulated during fermentation to express or 
produce hepatitis B viral coat proteins in massive quantities. 
These proteins self-associate to form aggregate complexes 
that are easily and cheaply purified. The degree of progress 
made with this particular vaccine is evident. It has been tested 
and licensed by the FDA and may be in use this year. 
This technology holds even greater promise for the produc-
tion of subunit vaccines for viruses where conventional 
approaches would simply not be safe. This is the case with the 
AIDS virus. In a disease that invariably is fatal , one can not 
consider using vaccines that are not assured to be 100% safe. 
Yet recombinant DNA technology permits molecular biolo-
gists to done and produce that portion of the virus that can 
elicit protective antibodies devoid of any infectious viral 
component. In fact, the cowpox virus, which was the very first 
vaccine used by Jenner to immunize humans against smallpox 
virus, is now being used as an expression vehicle for imm uno-
logically important coat proteins of the AIDS virus. The ele-
gant feature of this combined vaccine is that as the vaccinated 
host is producing antibodies against the smallpox group of 
viruses, they are also producing antibodies against the AIDS 
agents as well. This is a very important advance because the 
cowpox or vaccinia virus can accommodate a large amount of 
additional foreign genetic material. Therefore, a polyvalent 
vaccine that protects against a number of different viral agents, 
or strains thereof, can be produced. 
Probably the most advanced approach to vaccination is the 
production of immunogenic "designer," or engineered, pro-
teins. Using engineered peptides and polypeptides may well 
be better than using the natural forms produced through 
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conventional or recombinant DNA methods. This approach is 
a result of revolutionary new technologies such as x-ray crys-
tallographic analysis of protein structure, computerized 
modeling and simulation of molecular thermodynamics, 
computational chemistry, etc. These technologies now allow 
us to better understand the biochemical and physical features 
of the viral coat proteins essential to immunity so that better 
immunogens can be designed. Such analyses have resulted in 
improved peptide vaccines for polio virus. Various investiga-
tors have used molecular modeling techniques to study 
regions on the poliovirus that are most prominently exposed 
and would probably be recognized by the immune system. In 
conjunction with monoclonal antibody technology, virolo-
gists have identified specific segments of the coat proteins 
comprising the poliovirus virion that are responsible for 
inducing immunity. With this information, peptides corres-
ponding to these segments have been synthesized in vitro 
that have protected vaccinated animals from poliovirus 
infection. 
I now want to turn from prevention of disease to the diag-
nosis of viral diseases. Hybridoma technology has truly accel-
erated the development of viral diagnostic systems in recent 
years. Hybridomas are immortalized immune cells, which 
produce relatively pure antibodies (to viruses and other 
pathogenic agents) in large quantities. These monoclonal 
antibodies are much more valuable than antibodies extracted 
from the serum of immunized animals because of their innate 
specificity and strict homogeneity. Labelled monoclonal 
antibodies can be used to specifically "tag" biological sub-
stances such as membrane proteins that are only present on 
the surface of cancerous or infected cells. This facilitates the 
rapid diagnosis of a given pathological condition. For exam-
ple, an infection with Herpes simplex virus, type 1 (the cold 
sore virus) can be rapidly diagnosed in a few hours by staining 
infected cells with a fluorescently labeled monoclonal antib-
ody against a specific viral coat protein. Some bacterial infec-
tions can now be diagnosed in much the same way thereby 
allowing the physician to treat his/her patient with the most 
efficacious antibiotic or other drug. 
The other disease diagnosis area that has undergone a 
recent revolution because of biotechnology is the area of 
genetic disorders. Recombinant DNA technology permits the 
clinician to definitively identify and confirm that a patient is 
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carrying a defective gene based on the sequence of his or her 
DNA. Gene diagnosis at the molecular level is extraordinarily 
sensitive and is quickly becoming easier to perform in the 
common clinical laboratory. 
These new diagnostic techniques are particularly important 
developments for AIDS diagnosis. AIDS is a very frustrating 
disease for clinicians and patients because antibodies against 
the AIDS viral coat proteins may not be detectable for some 
time. Consequently, current serological tests, which rely on 
the presence of anti-AIDS antibodies in the blood may not 
accurately diagnose a potential AIDS victim until much later in 
life. The end result is that the potential exists to transmit the 
disease via transfusions from blood donors who were unaware 
that they were infected with the AIDS virus. So, in the future, 
we look to technologies such as gene synthesis and recombi-
nant DNA to be very beneficial in terms of early, accurate 
detection of pathological conditions. 
I will conclude with some brief comments about products 
for disease therapy using these new techniques. The advan-
tages of recombinant products are their unlimited availability, 
inexpensive manufacturing cost, high degree of purity, and 
their possibly greater intrinsic activity. I turn again to the field 
of virology for illustrations. When a virus infects a host cell, 
virus-specific genetic information, usually in the form of 
double-stranded ribonucleic acid (RNA), will be produced in 
the cell. This special form of RNA will evoke the production of 
minute quantities of interferon. Interferon travels to adjacent, 
uninfected cells and induces an anti-viral state that protects 
those adjacent cells from viral infection. Molecular biologists 
are taking advantage of this protective feature of cells and have 
isolated and cloned into bacteria, via recombinant DNA tech-
nology, the gene encoding interferon. Through bacterial fer-
mentation, large quantities of interferon can be produced. 
Testing of this agent can then be undertaken in an attempt to 
commercialize it as a new pharmacological product for pre-
venting virus infections. Other gene products such as clotting 
factors, blood proteins, clot-dissolvers like tissue plasmino-
gen activator (TPA), lymphokines like tumor necrosis factor, 
and many other beneficial substances have been or will be 
produced through biotechnology. The ready availability of 
such agents for the diagnosis and prevention or treatment of 
disease surely heralds the onset of a new age in human 
medicine. 
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